Phenomenex has unveiled the Biozen Native RP-1 and RP-5 chromatography columns, a groundbreaking solution that enhances the characterization of Antibody-Drug Conjugates (ADCs) in targeted cancer research. These new products allow for native reversed-phase separation with seamless online mass spectrometry (MS) detection—offering a revolutionary step forward in biotherapeutic analysis.

The Biozen Native RP columns are engineered with proprietary RP-1 and RP-5 particle technology, enabling efficient and robust resolution of Drug to Antibody Ratio (DAR) species, including challenging positional isomers. This innovation supports researchers with faster, higher-quality data acquisition while minimizing sample manipulation.

Designed for Precision and Speed in ADC Analysis

With traditional reversed-phase chromatography often requiring denaturing conditions, Biozen Native RP technology preserves the native structure of ADCs during separation, providing a more accurate picture of molecular characteristics. This advancement accelerates lead identification and optimization, crucial for therapeutic development.

Key Features of Biozen Native RP-1 and RP-5

• Proprietary RP-1 and RP-5 particle and surface chemistry

• Native reversed-phase separation for ADCs with intact structure

• Online mass spectrometry (MS) compatibility

• Rapid and robust resolution of all DAR species and isomers

• Reduced run times and sample manipulation

• Enhanced data quality for targeted biotherapeutics

Phenomenex continues to lead in chromatography innovation by delivering high-performance tools that support cutting-edge biopharmaceutical research.